Search clinical trials for: Glabellar Lines

Total 401 results

Revance Therapeutics, Inc.

Recruiting

Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines

Glabellar Frown Lines

United States
AbbVie

Recruiting

A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines

Glabellar Lines

China, Taiwan
Jetema USA Inc.

Not yet recruiting

Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines

Glabellar Lines
AbbVie

Recruiting

A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines

Upper Facial Lines

United States, Canada
Huons Biopharma

Not yet recruiting

To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)

Glabellar Lines
JHM BioPharma (Tonghua) Co. , Ltd.

Recruiting

A Phase I/II, Randomized, Double-blind, Placebo, and Active Controlled Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JHM03 in Subjects With Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
Protox Inc.

Not yet recruiting

The Efficacy and Safety of Protoxin in Subjects With Moderate to Severe Glabellar Lines

Glabellar Frown Lines
University of New Mexico
AbbVie

Not yet recruiting

Efficacy of Zinc Supplementation on Botox Treated Forehead Rhytids

Glabellar Frown Lines | Adjuvant Zinc May Increase the Efficacy of Botulinum Toxin | Zinc Supplementation for Botulinum Toxin Treatment of the Forehead | Botulinum Toxin, Cosmetic | Adjuvant Oral Zinc and Botulinum Toxin
Hugel

Recruiting

Evaluate the Safety and Efficacy of HG102 as Compared to Botox® in Subject With Moderate to Severe Glabellar Lines

Glabellar Lines

Korea, Republic of
ATGC Co., Ltd.

Recruiting

Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines

Glabellar Frown Lines

Korea, Republic of
Evolus, Inc.
Avania

Recruiting

Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines

Glabellar Frown Lines

Germany
Clinical Testing of Beverly Hills
Merz North America, Inc.

Not yet recruiting

Xeomin Treatment of Glabellar Lines Using OLD Versus COLD

Glabellar Frown Lines

United States
Clinical Testing of Beverly Hills
Allergan

Recruiting

Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines

Glabellar Frown Lines

United States
AbbVie

Completed

A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines

Glabellar Lines

United States, Canada, Germany, Hungary, Poland
Galderma R&D

Completed

Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines

Glabellar Frown Lines

United States
Merz North America, Inc.
Merz Pharmaceuticals GmbH

Completed

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines (ULTRA I)

Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)

United States
Eirion Therapeutics Inc.

Active, not recruiting

AI-09 In Subjects With Glabellar Lines, GL-101

Glabellar Frown Lines

United States
Daewoong Pharmaceutical Co. LTD.

Completed

DWP450 for Treating Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
AbbVie

Completed

Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

Japan
Henry Ford Health System

Active, not recruiting

Depth of Botulinum Neurotoxin Injection for Treatment of Glabellar Lines

Glabellar Frown Lines

United States
Daewoong Pharmaceutical Co. LTD.

Completed

Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines

Glabellar Lines

Korea, Republic of
Galderma R&D

Completed

Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines

Glabellar Frown Lines | Canthal Lines

United States
Medy-Tox

Completed

MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)

Lateral Canthal Lines | Glabellar Lines

United States, Russian Federation, Germany, Canada, Belgium, United Kingdom
Medy-Tox

Completed

Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines

Glabellar Frown Lines

Australia
Galderma R&D

Completed

Study Comparing Treatment With Alluzience vs Reconstituted Toxin (STAR)

Glabellar Frown Lines

Germany, United Kingdom
Clinical Testing of Beverly Hills
Evolus, Inc.

Completed

Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD

Glabellar Frown Lines

United States
Galderma R&D

Completed

Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin

Glabellar Lines

China
Medytox Korea

Completed

Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines

Glabellar Frown Lines

Korea, Republic of
Allergan

Completed

A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines

Glabellar Lines

United States, Canada
University of Southern California

Active, not recruiting

Split-Face Study Comparing Botox and Jeuveau in Treating Glabellar Lines

Glabellar Frown Lines

United States
CKD Bio Corporation

Completed

Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial

Glabellar Lines

Korea, Republic of
Protox Inc.

Completed

The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines

Glabellar Frown Lines

Korea, Republic of
Merz Aesthetics GmbH
Merz Pharmaceuticals GmbH

Completed

Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines

Moderate to Severe Glabellar Frown Lines

United States, Germany
Allergan

Completed

A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines

Glabellar Lines

United States
Galderma R&D

Completed

A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
Evolus, Inc.
ethica Clinical Research Inc.

Completed

Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines

Glabellar Frown Lines

United States
Galderma R&D

Completed

Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination (READY-3)

Glabellar Frown Lines (GL) | Lateral Canthal Lines (LCL)

United States, Canada
Allergan

Completed

AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines

Glabellar Lines

United States
Medy-Tox

Completed

MT10109L in the Treatment of Glabellar Lines

Glabellar Lines

United States, Belgium, Russian Federation
Medy-Tox

Completed

MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines

Lateral Canthal Lines | Glabellar Lines

United States, Germany, Canada
Allergan

Completed

A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines

Glabellar Lines

United States, Puerto Rico
Huons Co., Ltd.

Completed

Phase 2 of HU-045 in Glabellar Lines

Glabellar Lines

Korea, Republic of
Revance Therapeutics, Inc.

Completed

Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines

Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)

United States, Canada
Galderma R&D

Completed

Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines (READY-4)

Lateral Canthal Lines | Glabellar Lines

United States, Puerto Rico
Galderma R&D

Completed

Treatment of Moderate to Severe Glabellar Lines (READY-1)

Glabellar Frown Lines

United States, Canada
Allergan

Completed

A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines

Glabellar Lines

United States
AbbVie

Completed

A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines

Glabellar Lines

United States
Merz North America, Inc.

Terminated

Longitudinal Evaluation and Real-world Evidence of NT201

Glabellar Frown Lines and Canthal Lines and/or Horizontal Forehead Lines in the Upper Face

United States
Medy-Tox

Completed

MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)

Lateral Canthal Lines | Glabellar Lines

United States, Germany, Canada, United Kingdom
Chongqing Claruvis Pharmaceutical Co., Ltd.

Completed

A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China

3

Subscribe